Apollo Endosurgery said it picked software application platform developer Zillion to support its Orbera Coach program, which is designed to provide virtual aftercare support for patients undergoing Orbera gastric balloon weight loss procedures.
Through the program, which is powered by Zillion’s digital health platform, Orbera patients can access personally tailored 12-month programs designed to develop healthy habits to lower weight beyond the lifetime of the Orbera device.
“Apollo’s mission has always been to develop safe, effective and innovative solutions for weight loss and provide patients with the support they need to be successful with long-term weight loss. With Orbera Coach, patients now have 24/7 access to tools that can assist them along their weight loss journey and keep them focused on reaching and maintaining their fitness and nutrition goals,” Apollo CEO Todd Newton said in a press release.
Zillion’s platform will allow patients using the Orbera app to engage in face-to-face live video conferencing in many formats, track weight loss, journal their progress and provides a library for welness and healthy eating.
“Our partnership with Apollo Endosurgery underscores the mission of our company—enabling consumers to take control of their health and providing support that extends beyond visits to a healthcare provider. In order to see long-term, sustainable results, patients need access to easily accessible engagement tools to help them on the path to a healthier lifestyle,” Zillion prez Bill Van Wyck said in a prepared release.
Last August, Apollo Endosurgery said it won FDA pre-market approval for its weight-loss focused Orbera intragastric balloon.
The balloon device is designed to be inserted non-surgically in obese patients with body mass indexes of 30 to 40, the Austin, Texas-based company said. After insertion, the balloon is inflated to fill space in the stomach.
The post Apollo taps Zillion for Orbera patient app appeared first on MassDevice.
from MassDevice http://ift.tt/1TLE18B
Cap comentari:
Publica un comentari a l'entrada